1. What is the Chemxpert database?

Chemxpert database is a techno-commercial information platform developed and operated by Lifescience Intellipedia Pvt. Ltd. Our data provides valuable insights regarding sourcing, marketing, development, and regulatory functions for the entire Lifescience industry. The different industries covered by our data encompass APIs, FDFs, pharma intermediates, paints, dyes, polymers, biotechnology, biochemical, food additives, nutraceuticals, etc.

2. How can I subscribe to the Chemxpert database?

You can gain access to the Chemxpert database after subscribing to it by visiting this link: - https://chemxpert.com/pricing

3. How many countries' data is available on your portal?

The Chemxpert database covers more than 200 countries. We are working in the direction of expanding our data coverage in more countries.

4. What are the different sources you use for obtaining information?

The different sources we use for data collection are as follows: - • Primary researc • DMF, ANDA, & CEP list • Conferences, Exhibitions, & Tradeshow • Company annual reports • DMF, ANDA, & CEP list • Subject matter experts & KOL survey. Apart from these, our other valuable sources include application-wise manufacturers list, subscribed and non-subscribed databases, corporate partners, US FDA Orange book, publicly available sources, industry associates, national statistics, regulatory websites, etc. You can gain access to the Chemxpert database after subscribing to it by visiting this link: -https://chemxpert.com/sources

5. What is the expected time for account activation?

Your Chemxpert account will be activated instantly if the payment is made through our website. If you choose to use RTGS, NEFT, or IMPS systems for payment, your account will be activated within 24 hours.

10 Jul 2020
Admin
News Article

Algernon Begins Phase 2 Ifenprodil IPF And Chronic Cough Human Study In Australia

Algernon Pharmaceuticals, a clinical stage pharmaceutical development company, announced that it has begun screening patients for suitability for enrolment in its phase 2 idiopathic pulmonary fibrosis (IPF) and chronic cough clinical study of its re-purposed drug NP-120 (Ifenprodil). Ifenprodil is an NMDA receptor antagonist specifically targeting the NMDA-type subunit 2B.There are 5 sites in total participating in the study with 3 located in Australia and 2 in New Zealand. All 5 sites have now received ethics approval and all have successfully completed their site initiation.The Company originally decided to investigate Ifenprodil for both IPF and chronic cough after conducting several animal studies that showed the drug’s superior activity when compared with current standard of care treatments and a leading phase 3 drugs.Ifenprodil showed superiority in reducing fibrosis over two globally approved therapies for IPF, Roche’s Pirfenidone and Boehringer Ingelheim’s Nintedanib, in a well-established in vivo animal model study.Data from this study showed a 56.0% reduction in fibrosis vs untreated controls (p=0.015) in a 21-day bleomycin mouse model (treatment began on Day 7).Ifenprodil outperformed Merck’s phase 3 Drug MK-7264 (Gefapixant) in an Acute Cough Study by 110%, in a well-accepted acute cough in-vivo animal study. Pharmidex, a contract research organization (CRO) and a global leader in respiratory research conducted the cough study using the guinea pig citric acid challenge model. It should also be noted that unlike Gefapixant, Ifenprodil has no known taste disturbance.“There has been a significant amount of news flow recently related to our Ifenprodil COVID clinical trial program,” said Christopher J. Moreau, CEO of Algernon Pharmaceuticals. “However, while this is still an important focus for the company, this is a very appropriate time to remind our shareholders that Ifenprodil was initially selected for advancement into a human clinical trial based on its strong animal data for IPF and chronic cough. These are also important areas with significant unmet clinical needs. We look forward to updating the market when our first patient has been enrolled”.NP-120 (Ifenprodil) is an N-methyl-D-aspartate (NMDA) receptor antagonist specifically targeting the NMDA-type subunit 2B (Glu2NB). Ifenprodil prevents glutamate signalling. The NMDA receptor is found on many tissues including lung cells and T-cells, neutrophils

Let’s apply Data-Driven Pricing to Your APIs

Sick and tired of always wondering if you are being asked to pay the right price for your APIs? This empowers you with the answers you need to make the right decisions in the Global API market.

Chemxpert Database is one of the biggest and most comprehensive directories of pharma and chemicals, manufacturers, suppliers and information. Provided with current information on prices, demand and transactions, it gives you instant feedback on whether you are buying what is right and at the right time.

Start using market intelligence today and allow yourself to be in control in the API market.

Check it out today and make more informed sourcing decisions! Learn More!